Form 8-K - Current report:
SEC Accession No. 0001493152-26-024913
Filing Date
2026-05-22
Accepted
2026-05-22 08:00:37
Documents
11
Period of Report
2026-05-20
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 40332
  Complete submission text file 0001493152-26-024913.txt   205874

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE gtbp-20260520.xsd EX-101.SCH 3023
3 XBRL LABEL FILE gtbp-20260520_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE gtbp-20260520_pre.xml EX-101.PRE 22364
14 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3209
Mailing Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111
Business Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 261010805
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)